FDA Flags Only Minor Label Changes on NRx Ketamine ANDA Ahead of Nov. 10 Decision
NRXP sits 57% above its 52-week low of $1.62.
Summary
The FDA sent a Discipline Review Letter asking NRx for minor label changes on its preservative-free ketamine ANDA and for sample labeling with the proposed brand name. That is a late-stage, low-severity request — it means the review is essentially done and nothing substantive is blocking approval. It follows the September 16 8-K, when the FDA reclassified the amendment from Major to Minor and set a November 10, 2026 GDUFA goal date. For a company this size, a green light on the ketamine ANDA is the difference between a commercial product and another dilutive raise; the existing $20M ATM and the going-concern warning from the Q2 filing mean cash is tight. The November 10 GDUFA date is the binary event to trade.
At the time of this announcement, NRXP was trading at $2.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $112.1M. The 52-week trading range was $1.62 to $5.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.